Wednesday, October 14, 2026

Central Bank Gold Buying Spree Hits Abrupt Reversal After 15-Month Run

China and emerging market central banks drove gold prices to record highs through January 2026 with 15 consecutive months of purchases as part of dollar diversification strategies. The trend reversed sharply in March 2026, producing gold's worst monthly decline in over a decade despite bullish forecasts from major investment banks.

LM Salvado
LM Salvado

April 9, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Central Bank Gold Buying Spree Hits Abrupt Reversal After 15-Month Run
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

China's central bank extended gold purchases for 15 consecutive months through January 2026, part of a broader emerging market push that drove prices to all-time highs.1

The sustained buying represented a shift in reserve management away from U.S. dollar holdings. Central banks in emerging economies accumulated gold as a hedge against currency risk and geopolitical uncertainty.1

Gold reached record levels in early 2026 on the back of this institutional demand. Goldman Sachs maintained elevated price targets even as the metal approached peak levels.1

March 2026 marked an abrupt reversal. Gold posted its worst monthly decline in more than a decade, erasing gains built during the 15-month accumulation phase.1

The reversal occurred despite continued bullish positioning from Goldman Sachs and other major forecasters. The disconnect between analyst expectations and price action suggests a fundamental change in central bank behavior or broader monetary dynamics.1

Several factors may explain the shift. Central banks could be pausing purchases after rapidly expanding gold allocations. Currency markets may have stabilized enough to reduce diversification urgency. Or monetary policy changes in developed markets could be altering the calculus for reserve managers.

The timing raises questions about coordination among central banks. A synchronized pause in buying would indicate strategic repositioning rather than isolated decisions by individual institutions.

For currency markets, reduced central bank gold demand removes a key source of dollar selling pressure. Reserve managers buying gold typically sell dollar-denominated assets to fund purchases.

The March decline also tests the durability of gold's role as a reserve asset. If central banks resume buying, the March selloff represents a temporary correction. If they remain on the sidelines, it signals a more permanent shift in how reserve managers view gold versus fiat currencies.

Goldman Sachs has not revised its outlook despite the price decline, suggesting the bank sees the reversal as temporary rather than structural.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· April 4, 2026
    Goldman Sachs has blunt message on gold price for rest of 2026
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com